DELBERT Pharma news
Delbert Pharma announces the acquisition of Azactam® (aztreonam) from Bristol Myers Squibb
Paris, December 13, 2024 – Delbert Pharma, a French pharmaceutical company dedicated to safeguarding essential medicines, announces the acquisition of the injectable aztreonam (Azactam®) molecule from Bristol Myers Squibb. This acquisition represents a major milestone...
Delbert Pharma awarded Mission-driven company status
Paris, 09/27/2023 Delbert Pharma, a major player in the safeguarding and relocation of essential medicines, is proud to announce that it has officially been awarded Mission-driven company status in September 2023. This recognition, the fruit of intense collaborative...
New investment in Laboratoires Delbert
Vivalto Partners announces a significant investment in Laboratoires Delbert to support the company's development in the field of essential and orphan drugs. The historical investors - Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF...
Laboratoires Delbert signs the Supplier Relations and Purchasing Charter
Laboratoires Delbert is pleased to announce that it has signed the Responsible Purchasing and Supplier Relations (RFAR) charter. Committed since its creation to responsible approaches with its suppliers, on January 23, 2023 Laboratoires Delbert formalized these...
Article Le Monde: Delbert, saving essential medicines from dissapearing
Article published on Lemonde.fr, December 2, 2022. Since 2013, the pharmaceutical company has been fighting to breathe new life into essential old molecules threatened with disappearing from the therapeutic arsenal. With each new dossier that lands on its desk, the...
REQUEST MEDICAL INFORMATION - REPORT AN ADVERSE EVENT
To request medical information on DELBERT Pharma products or report an adverse event,
please write to pharmacovigilance@delbert.fr or contact us on + 33 1 46 99 68 20